<DOC>
	<DOCNO>NCT00565058</DOCNO>
	<brief_summary>This Phase II trial conduct multiple center evaluation pharmacodynamic activity overall response rate contribute combination agent GTI-2040 High Dose Cytarabine ( HiDAC ) Refractory Relapsed Acute Myeloid Leukemia ( AML ) .</brief_summary>
	<brief_title>Combination GTI-2040 Cytarabine Treatment Refractory Relapsed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients must unequivocal histologic diagnosis AML accord WHO classification . Patients must ( 1 ) refractory AML , define disease unresponsive initial treatment ; ( 2 ) relapse AML , define disease reoccurs treatment conventional high dose chemotherapy , without autologous stem cell support . Patients previously treat antisense oligonucleotides remain eligible absence significant doselimiting document toxicity directly attributable antisense agent . Age 1859 year old . Because dose adverse event data currently available use GTI2040 combination cytarabine patient &lt; 18 year age , child exclude study eligible future pediatric Phase 2 combination trial . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 ( Karnofsky &gt; 60 % ) . Patients central nervous system ( CNS ) involvement consider eligible study residual leukemic cell detectable cerebral spinal fluid follow intrathecal radiation therapy . Central line catheter administration GTI2040 infusion require patient enrol study . Ability understand willingness sign write informed consent document . Written informed consent require prior study procedure screen enrollment . Patients chemotherapy ( exception hydroxyurea ) radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Patients receive mitomycin C nitrosurea require 6 week recovery period enrollment . Patients prior allogeneic stem cell transplant . Patients may receive investigational agent part ongoing treatment . Patients follow abnormal clinical value ( unless abnormality parameter directly attributable malignancy ) : Resting cardiac ejection fraction &lt; 50 % Serum creatinine &gt; 1.5 mg/dL Total bilirubin &gt; 2x upper limit normal ( ULN ) ( unless due Gilbert 's syndrome ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3x ULN History allergic reaction attribute compound similar chemical biologic composition GTI2040 agent use study . Patients require chronic systemic anticoagulant therapy medical condition ( e.g. , previous history deep venous thrombosis , atrial fibrillation etc. ) . Heparin administration maintain central line patency ( i.e . catheter flush ) exclusion . Patients uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Serious medical psychiatric illness would prevent informed consent limit survival &lt; 4 week . Pregnancy breastfeed woman . The potential teratogenic effect risk GTI2040 nursing infant unknown . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . HIVpositive patient combination antiretroviral therapy ineligible patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>